Recombinant human IGA-J. chain dimer

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

5303901, 5303871, 4241301, 4241331, 435328, C12P 2108, C07K 1600, A61K 39395, C12N 506

Patent

active

060639059

ABSTRACT:
Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.

REFERENCES:
patent: 5698679 (1997-12-01), Nemazee
Carayannopoulos et al 1994 Proc. Natl. Acad. Sci. 91:8348-8352.
Quirakkoo et al 1996 Immunotechnology 2(3):219-228 Abstract Only.
Castilla et al., Interference of coronavirus infection by expression of immunoglobulin G (IgG) of IgA virus-neutralizing antibodies, J Virol., 71(7):5251-5258, 1997.
International Search Report dated Apr. 27, 1998 (PCT/US98/00614) (UTFD:505P).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Recombinant human IGA-J. chain dimer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant human IGA-J. chain dimer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human IGA-J. chain dimer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-259877

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.